CHERRY

Lemanik Holding S.A. reports losing the attribution of voting rights in Cherry following the sale of its subsidiary Lemanik Asset Management S.A., which has been renamed Fundsight S.A. As a result, the previously reported stake is no longer attributable to Lemanik; the sold entity still holds between 5% and 10% of Cherry’s voting rights. The notice was issued by BaFin by way of self-execution pursuant to § 6 para. 14 WpHG. » More on de.investing.com

Cherry placed 9,720,000 new bearer shares at a subscription price of EUR 1.04 per share in the rights issue approved on 12 June 2026, fully subscribed. As a result, share capital increases by EUR 9,720,000 to EUR 15,795,000. Prior to registration in the commercial register, the company generated gross proceeds of around EUR 10.1 million. » More on finanzen.net

Cherry SE reports preliminary, unaudited adjusted group EBITDA for H1 2026 of -4.0 million euros (H1 2025: -10.2 million euros excluding Active Key sale). Revenue fell to 40.0 million euros (H1 2025: 45.5 million euros excluding Active Key). The company attributes the improvement in adjusted EBITDA to a 12.3 percentage-point increase in gross margin and a cost base reduced by 7.0 million euros. The 2026 half-year report is delayed because the consolidated and annual financial statements for 2025 are still being audited; a new publication date will be announced. » More on de.investing.com

The management board of Cherry SE, with supervisory board approval, has resolved a cash capital increase with subscription rights, which would raise share capital by up to EUR 9.72 million to up to EUR 15.795 million. The subscription ratio is 5:8 (based on the reduced share capital), the subscription price per new share is EUR 1.04, and Cherry’s major shareholder, a subsidiary of Argand Partners, has committed to fully exercise its subscription rights. Shares not subscribed will be offered to selected investors in a private placement at no less than the subscription price; the offer will be made without a prospectus and the new shares are to be admitted to the Prime Standard of the Frankfurt Stock Exchange. Publication of the subscription offer details in the Bundesanzeiger is expected by mid‑July 2026. » More on de.investing.com

Cherry reports 2025 revenue of EUR 94.3 million, missing its target of more than EUR 100 million. Adjusted EBITDA remained negative at a loss of EUR 9.8 million, but showed a sequential improvement in Q4 to -EUR 4.9 million. Management under interim CEO Rogier Volmer reports significant working-capital improvements, inventory reductions and cost cuts, and has initiated an M&A review into a possible sale of DH&S or Peripherals. The digital-health business is viewed as a growth opportunity, with an expected additional 200,000 terminals by 2028 and a growing SaaS outlook that should bolster recurring revenues in the medium term. » More on de.investing.com